The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Blackstone Inc. (NYSE:BX) is exploring a possible sale of ZO Skin Health, the medical-grade skincare company founded by dermatologist Dr. Zein Obagi. Reuters reported that the business could be valued at around $2 billion. The process is still in the early stages, and Blackstone is working with Citigroup and Raymond James on the potential sale. ZO sells products such as cleansers, serums, and exfoliators mainly through doctors and skincare professionals.
The timing could work in Blackstone Inc. (NYSE:BX)'s favor. There has been growing interest from strategic buyers in skincare brands that have a clinical angle and are sold through physicians. These businesses can have an edge over regular over-the-counter skincare because customers tend to put more trust in products recommended by dermatologists and other professionals.
For Blackstone, selling ZO would also free up capital for other investments. The firm could return some of that money to its investors or put it into businesses where it sees more growth potential. For an asset manager of Blackstone's size, being able to turn investments into cash is important because it helps support future fundraising and new deals.
The broader beauty market also shows that buyers are still prepared to spend heavily on brands they believe have strong growth potential. Reuters has pointed to deals such as L'Oréal's $4.7 billion purchase of Kering's beauty business and Henkel's $1.4 billion acquisition of Olaplex as examples.